


Supplementary Fig S2.



Supplementary Figure S2. Combination treatment with OS2966 and oHSV does not enhance oHSV replication in intracranial glioma-bearing mice in vivo. A-B) Athymic nude mice bearing intracranial patient derived primary GBM30 tumors were treated with control IgG or OS2966 (5mg/kg) intraperitoneally on days -1, and 1 after oHSV therapy. **A)** Representative luciferase images of oHSV-treated mice with IgG/OS2966 on day 3. **B)** Data shown are total flux in each mouse treated with IgG or OS2966 on day 2 and 3 ($n = 4$). **C-D)** Athymic nude mice bearing intracranial U87 Δ EGFR tumors were treated with control IgG or OS2966 (5mg/kg) intraperitoneally on days -1, and 1 after oHSV therapy. **C)** Representative luciferase images of oHSV-treated mice with IgG/OS2966 on day 3. **D)** Data shown are total flux in each mouse treated with IgG or OS2966 on day 2 and 3 ($n = 5$).